Although anti-CD19 CAR therapy has shown great success, relapses associated with antigen escape have been increasingly linked to treatment failure, accounting for 10–65% of relapses in pediatric patients with relapsed/refractory (R/R) B-ALL in multiple clinical trials [4–7]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.